eWave Patch for Heart Monitoring
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial evaluates the ease of use of the WearLinq eWave patch, a device that monitors heart activity. Participants will wear the patch for either 7 or 30 days to assess its effectiveness. This trial may suit adults who can use a smartphone app and have no skin allergies or electronic implants like pacemakers. As an unphased trial, it provides a unique opportunity to contribute to the development of innovative heart monitoring technology.
Do I need to stop taking my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications.
What prior data suggests that the eWave Patch is safe for heart monitoring?
Studies have shown that the eWave Patch is safe for use. This wearable heart monitor has received FDA approval, meeting safety standards for checking heart activity. This approval confirms that the patch is safe and unlikely to cause harm. The eWave Patch uses six sensors to offer a detailed view of heart activity, aiding in the detection of heart issues without causing discomfort. In summary, research suggests that the eWave Patch is safe and easy to use for heart monitoring.12345
Why are researchers excited about this trial?
The eWave Patch is unique because it offers a non-invasive way to continuously monitor heart activity using a wearable patch. Unlike traditional heart monitoring systems that can be bulky and uncomfortable, this patch is designed to be lightweight and easy to wear, allowing for more natural daily activities. Researchers are excited about the potential of the eWave Patch to provide real-time, detailed cardiac data over an extended period—up to 30 days—without the need for frequent hospital visits. This could lead to earlier detection of heart issues and more personalized treatment plans.
What evidence suggests that the eWave Patch is effective for heart monitoring?
Research shows that the eWave Patch provides a detailed view of the heart using six different sensors, surpassing the usual single-sensor patches that can miss some heart events. In this trial, participants will apply the WearLinq patch for either 7 or 30 consecutive days, depending on their assigned study arm. Studies indicate that wearable heart monitors like the eWave can perform as effectively as the traditional 24-hour Holter monitor in tracking heart activity over longer periods. This capability helps doctors detect infrequent heart issues. The eWave's clear heart readings make it a valuable tool for monitoring heart health.12467
Who Is on the Research Team?
Chris Daniel
Principal Investigator
WearLinq, Inc.
Are You a Good Fit for This Trial?
This trial is for adults over 18 who can consent and use a smartphone app. They must be willing to shave the area where the eWave patch will be placed if necessary. It's not for those with allergies to adhesives, skin conditions affecting the chest, electronic implants like pacemakers, or pregnant individuals.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive and apply the WearLinq patch for 7 consecutive days
Extended Use
A subset of participants will continue to use the WearLinq patch for 30 consecutive days
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- eWave Patch
Trial Overview
The study tests how easy it is for people to use the WearLinq eWave patch, which monitors heart activity through ECG readings. Participants will wear this device and interact with its accompanying smartphone app.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Participants will receive and apply the WearLinq patch for 30 consecutive days
Participants will receive and apply the WearLinq patch for 7 consecutive days
Find a Clinic Near You
Who Is Running the Clinical Trial?
Wearlinq
Lead Sponsor
ABio Clinical Research Partners
Collaborator
Citations
A Usability Study of a Multi-channel ECG Monitoring Device
Study Overview. Brief Summary. This study it to evaluate the usability of the WearLinq eWave patch in a general adult population.
Wearlinq Labs - Elevating the Standard of Cardiac Monitoring
As a cardiac monitor with 6 distinct leads, the eWave provides cardiologists with a detailed multidimensional view of the heart with exceptional ECG clarity.
Wearable ECG patch monitoring for 72 h is comparable ... - PMC
We sought to compare the diagnostic efficacy of a 72-hour wearable electrocardiography (ECG) patch monitoring with a conventional 24-hour Holter monitoring for ...
Noninvasive Hemodynamic Assessment by a Sensor Patch
The purpose of this study was to evaluate a multimodal sensor patch's (SANSA) assessment of DFT, pre-ejection period (PEP), and left ventricular ejection time ...
5.
hitconsultant.net
hitconsultant.net/2025/12/17/wearlinq-raises-19m-to-scale-fda-cleared-wireless-cardiac-monitor/Why Cardiologists Are Betting $19M on Wearlinq to Fix ...
Single-Lead Patches: Easy to wear but provide a limited “view” of the heart, often missing intermittent events or subtle electrical changes.
WearLinq to expand access to FDA-cleared wearable ECG
eWave, a 6-lead wearable ECG monitor, recently received FDA 510(k) clearance. San Francisco-based WearLinq's acquisition also comes on the heels ...
Wearlinq raises $14M to bring remote heart monitoring ...
Overcoming the limitations of previous monitoring technologies, eWave is capable of "transforming continuous cardiac signals into actionable ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.